Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul;7(4):603-10.
doi: 10.1161/CIRCOUTCOMES.113.000800. Epub 2014 Jul 8.

Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiative

Anthony A Bavry  1 , Fridtjof Thomas  2 , Matthew Allison  2 , Karen C Johnson  2 , Barbara V Howard  2 , Mark Hlatky  2 , JoAnn E Manson  2 , Marian C Limacher  2
Affiliations
Randomized Controlled Trial

Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiative

Anthony A Bavry et al. Circ Cardiovasc Qual Outcomes. 2014 Jul.

Abstract

Background: Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) are sparse. We hypothesized that regular NSAID use is associated with increased risk for cardiovascular events in postmenopausal women, and that this association is stronger with greater cyclooxygenase (cox)-2 when compared with cox-1 inhibition.

Methods and results: Postmenopausal women enrolled in the Women's Health Initiative were classified as regular users or nonusers of nonaspirin NSAIDs. Cox regression examined NSAID use as a time-varying covariate and its association with the primary outcome of total cardiovascular disease defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Secondary analyses considered the association of selective cox-2 inhibitors (eg, celecoxib), nonselective agents with cox-2>cox-1 inhibition (eg, naproxen), and nonselective agents with cox-1>cox-2 inhibition (eg, ibuprofen) with the primary outcome. Overall, 160 801 participants were available for analysis (mean follow-up, 11.2 years). Regular NSAID use at some point in time was reported by 53 142 participants. Regular NSAID use was associated with an increased hazard for cardiovascular events versus no NSAID use (hazard ratio [HR], 1.10; 95% confidence interval, 1.06-1.15; P<0.001). Selective cox-2 inhibitors were associated with a modest increased hazard for cardiovascular events (hazard ratio, 1.13; 1.04-1.23; P=0.004 and celecoxib only: HR, 1.13; 1.01-1.27; P=0.031). Among aspirin users, concomitant selective cox-2 inhibitor use was no longer associated with increased hazard for cardiovascular events. There was an increased risk for agents with cox-2>cox-1 inhibition (HR, 1.17; 1.10-1.24; P<0.001 and naproxen only: HR, 1.22; 1.12-1.34; P<0.001). This harmful association remained among concomitant aspirin users. We did not observe a risk elevation for agents with cox-1>cox-2 inhibition (HR, 1.01; 0.95-1.07; P=0.884 and ibuprofen only: HR, 1.00; 0.93-1.07; P=0.996).

Conclusions: Regular use of selective cox-2 inhibitors and nonselective NSAIDs with cox-2>cox-1 inhibition showed a modestly increased hazard for cardiovascular events. Nonselective agents with cox-1>cox-2 inhibition were not associated with increased cardiovascular risk.

Clinical trial registration url: www.clinicaltrials.gov. Unique identifier: NCT00000611.

Keywords: anti-inflammatory agents, non-steroidal; coronary artery disease; myocardial infarction; stroke.

PubMed Disclaimer

Conflict of interest statement

Disclosures

Dr Bavry is a contractor for the American College of Cardiology's Cardiosource. The other authors report no conflicts.

Figures

Figure 1
Figure 1
Of all 161,808 Women Health Initiative (WHI) enrollees, 160,801 were utilized in the analysis. Women were only excluded due to missing baseline covariates (n = 311) if the number of women with that missing variable was small. Otherwise, a separate factor level “missing” was maintained in categorical variables.
Figure 2
Figure 2
Adjusted hazard ratios for the primary outcome (cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke) and secondary outcomes for regular NSAID use versus no NSAID use. Group 1=cox-2 selective agents, group 2=non-selective agents with cox-2>cox-1 inhibition, group 3=non-selective agents with cox-1>cox-2 inhibition.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med. 2005;352:1092–1102. - PubMed
    1. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021–2029. - PubMed
    1. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86. - PMC - PubMed
    1. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2:349–360. - PubMed
    1. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–313. - PubMed

Publication types

Substances

Associated data